Business
Personalis Announces Four Abstracts Accepted for Presentation at AACR Annual Meeting 2023
New findings reinforce potential of company’s highly-sensitive MRD offerings for earlier recurrence detection and therapy response monitoring FREMONT,
About this update from Personalis, Inc.
[{"type":"text","content":"\nNew findings reinforce potential of company’s highly-sensitive MRD offerings for earlier recurrence detection and therapy response monitoring\n\n FREMONT, Calif.--(BUSINESS WIRE)--\nPersonalis, Inc. (Nasdaq: PSNL) today announced it is presenting new research data as scientific posters at the American Association for Cancer Research (AACR) Annual Meeting 2023, which convenes from April 14-19, 2023 in Orlando, Florida.\n\nThe data highlights the power of the company’s highly-discerning technologies that both characterize and monitor cancer, including initial research findings from a collaboration with University Medical Center Hamburg-Eppendorf (UKE) and its new Fleur-Hiege Center for Skin Cancer Research, where Dr. Klaus Pantel, Dr. Christoffer Gebhardt, and team are using NeXT Personal® to track tumor response to immunotherapy (IO) in patients with melanoma, with the aim of gathering evidence to advance the use of ultra-sensitive minimal residual disease (MRD) detection in routine clinical practice for IO therapy monitoring.\n\n“We are encouraged by initial findings from our research with Dr. Pantel and his team at UKE, which show that highly sensitive detection of circulating tumor DNA (ctDNA) may improve our ability to predict responses or resistance to therapy earlier than imaging,” said Sean Boyle, Executive Director of Scientific Applications at Personalis. “Our deep expertise in genomic sequencing and commitment to scientific excellence have laid the foundation not only for our own MRD advancements, but also for exceptional partnerships with leaders in the field of oncology.”\n\nBoyle added, “We are also excited to share updates on NeXT Personal performance, with research data that shows the highly sensitive assay can detect MRD even in challenging samples, at earlier time points. The addition of clinically relevant tumor-agnostic actionable content makes NeXT Personal unique in its ability to both detect MRD and identify clinically relevant mutations that may be missed with other assays.”\n\nDetails of the Personalis abstracts are outlined below, and further details about the poster presentations can be found at this link.\n\nTitle: Ultra-sensitive tumor-informed ctDNA assay predicts survival in advanced melanoma patients treated with immune checkpoint inhibition\nOverview: Immune checkpoint inhibition (ICI) elicits cl...